Summary:
- The FDA has approved the use of the drug liraglutide (brand name Saxenda) for the treatment of obesity in children and adolescents aged 12-17.
- Liraglutide is a type of medication called a GLP-1 agonist, which helps regulate appetite and blood sugar levels, leading to weight loss.
- Clinical trials showed that liraglutide, combined with lifestyle changes, helped children and teens with obesity lose a significant amount of weight and improve their health markers, though long-term safety data is still being collected.